Skip to main content
Cell & Gene

Manufacturing CGTs: Should I Use A CDMO?

September 30, 2022
著者
Deeona R. GaskinRaj D. Pai

Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).

Click here to view the article.

連絡先

Gaskin, Deeona R.
パートナー
Pai, Raj D.
パートナー

関連公式ブログ

得意分野

Suggested News & Insights

AI Collaborations – From Strategic License to Strategic AcquisitionJune 15, 2026
GoodLifeSci
The EU AI Act’s Machinery Exemption: Does It Extend to Surgical Robotics?June 11, 2026
GoodLifeSci
Most-Favored-Nations Drug Pricing Policy: White House Quietly Releases Report Describing Voluntary MFN DealsMay 29, 2026
GoodLifeSci
FDA’s Elsa at Eleven Months: AI-Powered Operations and One-Day Inspections Signal a New Oversight ParadigmMay 20, 2026
GoodLifeSci
EU Pharma Package: Compromise Text Published – Best Efforts Required (Part 2)May 18, 2026
GoodLifeSci
Navigating the European Health Data Space Regulation: An (Uneasy) Marriage Between EHDS and GDPR (April 2026, Part 2)April 14, 2026
GoodLifeSci